Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.
Fiche publication
Date publication
novembre 2022
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr LEPAGE Côme, Dr SPAETH Dominique, Pr MANFREDI Sylvain
Tous les auteurs :
Manfredi S, Dior M, Bouche O, Barbier E, Hautefeuille V, Guillet M, Turpin J, Bourgeois V, Helene DO, Desgrippes R, Audemar F, Molin Y, Locher C, Chatellier T, Lecomte T, Baize N, Lecaille C, Spaeth D, Goujon G, Lepage C, Tougeron D,
Lien Pubmed
Résumé
Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are available on the routine daily management of advanced gastric or gastroesophageal junction cancers. We aimed to describe chemotherapy practices, tolerance, and efficacy overall survival (OS) and Progression free survival (PFS) in a prospective French cohort.
Mots clés
cohort, gastric cancer, real life, strategy
Référence
Cancer Med. 2022 11 16;: